US2020188516A1PendingUtilityA1

Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine

69
Assignee: SANOFI AVENTIS DEUTSCHLANDPriority: Nov 13, 2009Filed: Oct 28, 2019Published: Jun 18, 2020
Est. expiryNov 13, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Annika HagendorfGerrit HauckWerner MuellerIsabell SchoettleVerena Siefke-HenzlerKatrin Tertsch
A61K 38/26A61K 38/28A61K 47/183A61P 3/04A61K 47/10C07K 14/605A61K 38/2278A61K 47/20A61P 7/12A61K 9/0019A61P 3/10A61K 9/08A61P 3/08A61P 5/50C07K 14/62A61P 3/00
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Claims

exact text as granted — not AI-modified
1 . An aqueous liquid composition consisting essentially of the following constituents:
 (a) desPro 36 exendin-4(1-39)-Lys6-NH 2 ,   (b) Gly(A21)-Arg(B31)-Arg(B32) human insulin,   (c) zinc,   (d) m-cresol,   (e) L-methionine,   (f) glycerol, and   (g) water.   
     
     
         2 . The composition of  claim 1 , further comprising hydrochloric acid and sodium hydroxide as needed achieve a pH of 3.5 to 4.5. 
     
     
         3 . The composition of  claim 1 , further comprising hydrochloric acid and sodium hydroxide as needed achieve a pH of about 4.5.

Join the waitlist — get patent alerts

Track US2020188516A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.